Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine


  • The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease
  • The study will have efficacy endpoints as progression-free survival (PFS), treatment failure-free survival (TFFS), overall survival (OS), overall response rate (ORR), and duration of response (DoR)
  • LOXO-292 is an oral investigational new medicine targeted to inhibit native RET signaling as well as anticipated acquired resistance mechanisms and has also received Breakthrough Therapy designation in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter